|Bid||0.0400 x N/A|
|Ask||0.0450 x N/A|
|Day's Range||0.0400 - 0.0450|
|52 Week Range||0.0300 - 0.1300|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Acerus Pharmaceuticals Corporation ("Acerus" or the "Company") (TSX: ASP, OTCQB: ASPCF) today announced that it received a waiver letter from SWK Funding LLC ("SWK") related to the required Minimum Revenue Covenant for Q4-2020 in its existing credit facility with Acerus.
Acerus Pharmaceuticals Corporation ("Acerus" or the "Company") (TSX: ASP, OTCQB: ASPCF) is pleased to announce that, further to its press release dated November 25, 2020 with respect to the completion of Acerus’ rights offering (the "Rights Offering"), Acerus issued 526,600,000 common shares of Acerus ("Common Shares") under the Rights Offering at a price of $0.025 per share for gross proceeds of approximately $13,165,000.